EC Grants Orphan Drug Designation to Vico Therapeutics’ Oligonucleotide SCA Therapy

Article

The EC has granted Vico Therapeutics with orphan drug designation for its investigational antisense oligonucleotide therapy for the treatment of SCA.

The European Commission (EC) has granted Vico Therapeutics with orphan drug designation for its investigational antisense oligonucleotide therapy (VO659) for the treatment of Spinocerebellar Ataxia (SCA).

According to a Feb 10, 2021 press release, the orphan designation was granted based on a positive opinion from the European Medicines Agency Committee for Orphan Medicinal Products. A previous orphan designation has also been granted for VO659 for the treatment of Huntington Disease.

“[SCA] make up a great part of the so called polyglutamine disorders, debilitating and progressive diseases, leading to significant impairment of mobility, speech, and multiple other daily activities of patients suffering from this condition. So far, there is no treatment which can halt the progression of these diseases,” said Rupert Sandbrink, chief medical officer at Vico, in the press release.“Our investigational RNA modulating therapy is designed to lower the mutant protein levels causing these neurodegenerative diseases. We’re pleased to receive orphan drug designation, which recognizes both the unmet medical need for patients living with spinocerebellar ataxias, and the potential of our approach.”

Source: Vico Therapeutics

Recent Videos
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Kate Coleman, vice president regulatory affairs, quality and compliance, Arriello, chats about industry trends and technological advances.
Industry Outlook 2025: The Rising Prominence of AI in Pharma
Adam Sherlock, CEO of Qinecsa, discusses the changing political landscapes in the US and Europe and how that may affect the bio/pharma industry.
Related Content
© 2025 MJH Life Sciences

All rights reserved.